1 **Title:** Comparison of serum PSA and IMPDH-2 in Predicting Aggressive Prostate Cancer: A Cross-sectional
2 Study
3
4 **Article type:** Original Article
5
6 **Author names:**
7 1. Ahmed Mohammed Umar
8 2. Ismaila Arzika Mungadi
9 3. Ngwobia Peter Agwu
10 4. Abdulwahab-Ahmed Abdullah
11 5. Abubakar Sadiq Muhammad
12 6. Abdullahi Khalid
13 7. Emmanuel Ugbede Oyibo
14
15 **Degrees and Affiliations:**
16 1. MD. First-year PhD. Urology Student. Usmanu Danfodiyo University/Usmanu Danfodiyo University
17 Teaching Hospital/Sokoto, Nigeria.
18 2. MBBS, FRCS(Ed), FWACS. Usmanu Danfodiyo University/Usmanu Danfodiyo University Teaching
19 Hospital/TetFund Centre of Excellence in Urology and Nephrology, Sokoto, Nigeria.
20 3. MBBS, FMCS. Usmanu Danfodiyo University/Usmanu Danfodiyo University Teaching Hospital/Sokoto,
21 Nigeria.
22 4. MBBS, FMCS. Usmanu Danfodiyo University/Usmanu Danfodiyo University Teaching Hospital/Sokoto,
23 Nigeria.
24 5. MBBS, FMCS, FWACS. Usmanu Danfodiyo University/Usmanu Danfodiyo University Teaching
25 Hospital/Sokoto, Nigeria.
26 6. MBBS, FWACS. Usmanu Danfodiyo University/Usmanu Danfodiyo University Teaching
27 Hospital/Sokoto, Nigeria.
28 7. MBBS, FMCS, FWACS. Usmanu Danfodiyo University/Usmanu Danfodiyo University Teaching
29 Hospital/Sokoto, Nigeria
30
31 **ORCID (Open Researcher and Contributor Identifier**
32 1. https://orcid.org/0000-0001-5811-0489
33 2. https://orcid.org/0009-0007-2869-3776
34 3. https://orcid.org/0000-0001-9199-5311
35 4. https://orcid.org/0000-0002-4794-7248
36 5. https://orcid.org/0000-0002-0404-9042
37 6. https://orcid.org/0000-0001-5984-3553
38 7. https://orcid.org/0000-0002-4470-2587
39

1   **About the author:** Ahmed M Umar is a Doctor of Medicine who graduated summa cum laude from the Latin

2   American of Medicine, Havana, Cuba. I am presently undertaking PhD Urology at Usmanu Danfodiyo University,

3   Sokoto State, Nigeria. I am in my first year of a 3-year program.

4

5   **Corresponding author email:** aumohammed11@gmail.com

6

14

15   **Conflict of interest statement by authors:** We have no conflict of interest to declare

16

17   **Compliance with ethical standards:** The health research and ethics committee of Usmanu Danfodiyo

18   University Teaching Hospital approved the study with reference number UDUTH/HREC/2019/No. 852

19

20   **Authors Contribution Statement:**

21   Conceptualization: AMU, IAM, NPA, AAA. Data Curation: AMU, EUO. Formal Analysis: AMU. Funding

22   Acquisition: AMU. Methodology: AMU, ASM, AK. Project Administration: IAM. Resources: AMU,

23   EUO. Software: AMU. Supervision: IAM, NPA, AAA, ASM. Validation: AMU, NPA, ASM. Visualization:

24   AMU. Writing - Original Draft: AMU, AK, EUO. Writing - Review Editing: AMU, IAM, NPA, AAA, ASM, AK.

25   •   Conceptualization: AMU, IAM, NPA, AAA.

26   •   Data Curation: AMU, EUO.

27   •   Formal Analysis: AMU.

28   •   Funding Acquisition: AMU.

29   •   Methodology: AMU, ASM, AK.

30   •   Project Administration: IAM.

31   •   Resources: AMU, EUO.

32   •   Software: AMU.

33   •   Supervision: IAM, NPA, AAA, ASM.

34   •   Validation: AMU, NPA, ASM.

35   •   Visualization: AMU.

36   •   Writing - Original Draft: AMU, AK, EUO.

37   •   Writing - Review Editing: AMU, IAM, NPA, AAA, ASM, AK, EUO

38

39   **Manuscript word count:** 3657

40   **Abstract word count:** 250

1   **Number of Figures and Tables:** 10

2

3   **Personal, Professional, and Institutional Social Network accounts:**

4   - **Twitter:** @docmed2012

5   - **Instagram:** docmed2012

6   - **Linkedin:** Ahmed Mohammed Umar

7

IJMS

1 **ABSTRACT.**

2

3 **Background:** Prostate cancer is a cause of morbidity and mortality among men globally. This study compared

4 serum Prostate-Specific Antigen (PSA) and Inosine Monophosphate Dehydrogenase-2 (IMPDH-2) in predicting

5 aggressive prostate cancer.

6 **Methods:** Sixty-three prostate adenocarcinoma patients were recruited for this quantitative descriptive cross-

7 sectional study. Their serum was assayed for IMPDH-2 and PSA. Serum IMPDH-2 and PSA correlations with

8 Gleason score and ISUP Grade Groups were determined using Spearman's rho and Kendall tau correlation

9 coefficients, respectively. The magnitude of the correlation was assessed by calculating the coefficient of

10 determination for the respective analysis (R^2). Similarly, regression analysis and receiver operating

11 characteristic (ROC) curve were used to assess the ability of the biomarkers to predict aggressive prostate

12 cancer. Levels of statistical significance were set as $p < 0.05$.

13 **Results:** The mean age was 68.6 years. The mean serum IMPDH-2 and PSA were 76.2pg/ml and 65.9ng/ml

14 respectively. Serum IMPDH-2 did not predict aggressive prostate cancer; ($r = 0.08$, $p = 0.55$ Spearman rho), (τ

15 $= 0.03$, $p = 0.79$ Kendal tau). Serum PSA weakly predicted aggressive prostate cancer; ($r = 0.30$, $p = 0.02$

16 Spearman rho), ($\tau = 0.21$, $p = 0.04$ Kendal tau). It was responsible for 10.1 and 8.8% of Gleason score and

17 ISUP grade group variances respectively. However, it did not significantly outperform IMPDH-2 in predicting the

18 Gleason score ($p = 0.53$).

19 **Conclusion:** PSA weakly predicted aggressive prostate cancer but did not statistically significantly outperform

20 IMPDH-2. As such, none is sufficiently accurate in predicting aggressive prostate cancer when used in isolation.

21

22 **Key Words**: *Inosine Monophosphate Dehydrogenase-2, IMPDH2 Protein, Prostate Cancer, Prostate Specific*

23 *Antigen, PSA.*

24

1 **INTRODUCTION.**

2

3 Prostate cancer is the second most common cancer among men globally and is only superseded by lung
4 cancer.[1] In Africa, It is the most common cancer among men with an estimated 104,050 new cases based on
5 2022 records.[1] The true burden of prostate cancer in Nigeria is unknown due to underreporting and poor
6 statistics.[2] However, it is reported to be the most common male cancer in Nigeria, constituting 37.5% of all newly
7 diagnosed male cancers.[1] Furthermore, It is the most common cause of cancer deaths in Nigerian men.[1] African
8 ethnicity is a significant risk factor for PCa and the disease tends to appear at an earlier age and is often more
9 aggressive. Other risk factors are advanced age, family history of PCa, red meat, diet rich in fat, and dairy
10 products.[3] Most of our patients present with locally advanced or metastatic disease. This makes prostate cancer
11 an important public health concern in Nigeria. Prostate cancer is the fifth leading cause of mortality among men
12 and the highest death rates have been reported among African descent.[4] The global burden of the disease is
13 on the rise due to widespread prostate specific antigen (PSA) testing and the use of transrectal ultrasound-
14 guided prostate biopsy.[5–7]
15 The use of serum prostate specific antigen has led to earlier detection of prostate cancer at the expense of
16 overdiagnosis.[8] The greatest limitation of PSA is its poor specificity and low ability to distinguish aggressive
17 from non-aggressive prostate cancer.[8] Identifying patients with aggressive prostate cancer is indispensable as
18 over 80% of them will develop skeletal complications with its attendant negative effect on their quality of life.[8]
19 The correct grading of prostate cancer is vital for management decision-making. At present, Gleason grading is
20 used to predict the aggressive nature of prostate cancer with higher Gleason scores corresponding to more
21 aggressive disease.[8] Hence, the Gleason score is one of the most powerful prognostic predictors of prostate
22 cancer.[9] The Gleason grading system has undergone revisions over the years to improve on its limitations. One
23 such revision is assigning a score of 6 as the lowest grade on prostate needle biopsy and developing a new
24 grading system.[9] This new grading system proposed in 2013 by a group from Johns Hopkins Hospital has five
25 grade groups. These grade groups are more accurate in predicting disease progression than the traditional
26 Gleason grading system.[9] The system was validated and proposed by the International Society of Urological
27 Pathologists (ISUP) consensus. It was later adopted by the 2016 World Health Organization (WHO)
28 classification of prostate tumors.[9,10]
29 Even though the Gleason score and ISUP grade group are more reliable than PSA in predicting aggressive
30 prostate cancer, they can miss some patients with aggressive disease. This is because high-grade foci of
31 prostate cancer can be missed during trucut needle biopsy. Furthermore, prostate biopsy is an invasive
32 procedure with some complications. Because of these limitations, a reliable, accessible, non-invasive, and
33 affordable screening modality for aggressive prostate cancer is required to improve diagnosis and management.
34 This desirable biomarker will reduce the need for repeated biopsies to identify patients with aggressive disease.
35 It will also help identify disease upgrades in patients undergoing active surveillance or watchful waiting.
36 Serum inosine monophosphate dehydrogenase (IMPDH) may assume this role. It is a rate-limiting enzyme
37 involved in a crucial step in the de novo pathway of purine nucleotide biosynthesis, which is essential for DNA
38 synthesis.[11] IMPDH catalyzes the oxidation of inosine 5'—monophosphate to xanthosine 5'—monophosphate.[12]
39 It is associated with cell growth, malignant transformation, and differentiation.[13] The enzyme exists in two
40 isoforms, and Isoenzyme 2 is preferentially upregulated in malignant cells, including prostate, bladder, and renal
41 cancers.[11] This enzyme was chosen in this study because high-grade aggressive cancers have higher cell

5

1 replication and, hence, higher DNA requirements, which may translate to higher expression of the enzyme.
2 Furthermore, previous reports have also found high expression of IMPDH-2 to be associated with aggressive
3 human nasopharyngeal carcinoma.[11,13] Similarly, overexpression of IMPDH-2 in hepatocellular carcinoma
4 (HCC) tissues was reported to be closely related to aggressive disease.[11] Likewise, a study in Poland found
5 that serum IMPDH-2 had some usefulness in predicting aggressive prostate cancer.[14] Given the fact that the
6 previous study was in a European population, this study aims to compare serum PSA and IMPDH-2 in predicting
7 aggressive prostate cancer in our predominantly black population. We hypothesize that serum IMPDH-2 was
8 better than PSA in predicting aggressive prostate cancer.
9
10

METHODS

This hospital-based quantitative, descriptive cross-sectional study was conducted at the Institute of Urology and Nephrology of Usmanu Danfodiyo University/Teaching Hospital, Sokoto, Nigeria from January to December 2020. A non-randomized sampling technique was used whereby consecutive patients with adenocarcinoma of the prostate were recruited into the study. A minimum estimated sample size of 54 subjects was calculated using the formula for calculating sample size for a cross-sectional study with a quantitative outcome variable.[15] Details of the calculation are contained in the supplementary file.

The inclusion criteria were all newly diagnosed patients with a histologically confirmed adenocarcinoma of the prostate who presented to the urology clinic of Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria. The exclusion criteria were patients on any form of treatment for prostatic diseases such as 5-alpha reductase inhibitors, androgen deprivation therapy, and radiation therapy. Patients who had any form of prostatectomy, those with any histological type of cancer other than adenocarcinoma, and those who refused to consent to be enrolled in the study were similarly excluded.

All enrolled participants were clinically evaluated through detailed history taking and physical examinations. Similarly, the participants had their routine laboratory tests that included full blood count (FBC), serum electrolytes, urea, creatinine (EUCr), urinalysis and urine microscopy, culture, and sensitivity (M/C/S). Additionally, all participants had their serum assayed for IMPDH-2 and PSA by a competent laboratory scientist at the chemical pathology department of Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria using the Sunlong® Biotech IMPDH-2 enzyme-linked immunosorbent assay (ELISA) kit (REF SL3371Hu) and PSA AccuBind® ELISA kit (REF 2125-300A) based on the manufacturers' instruction as contained in the instruction manual.[16,17]

For the assay of the biomarkers, the collected blood samples were allowed to clot for 30 minutes. The samples were then centrifuged at 2000 rpm for 20 minutes. The supernatant serum was collected and stored at -20°C. Any haemolyzed blood sample was discarded and a fresh blood sample was collected because it could interfere with the result. The details of the procedure are contained in the supplementary file. The diagnosis of PCa was made through a systematic prostate needle biopsy obtained via transrectal ultrasound guidance using Mindray® Diagnostic Ultrasound System DC-30. Additional targeted biopsies were obtained in subjects with suspicious nodules using a Bard® Magnum spring-loaded biopsy gun. The histopathologists at the histopathology department of Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria made the histological diagnosis and Gleason grading.

The patients were grouped into the five ISUP Grade groups of increasing aggressiveness of the tumor. These grade groups are 1 (Gleason score ≤ 6), 2 (Gleason score 3+4), 3 (Gleason score 4+3), 4 (Gleason score 8), and 5 (Gleason score 9 – 10). The research data were collected using structured pro-forma. At the end of the study, the data were entered into and analyzed using IBM® SPSS® statistics for Windows, version 23.0. Multiple statistical analysis was performed to assess the ability of the biomarkers to predict aggressive prostate cancer. The first was to determine the correlation of serum IMPDH-2 and PSA with the Gleason score using Spearman's rho correlation coefficient as the data were not normally distributed. The correlation with the ISUP grade group was determined using the Kendall tau correlation coefficient. The correlation was graded as very weak if r (< 0.3), weak (0.3 – 0.4), moderate (0.5 – 0.6), or strong (≥ 0.7). The magnitude of the correlation was determined by calculating the coefficient of determination for the respective analysis = (R^2).[18] The second statistical analysis

7

1 was the linear regression analysis to establish a relationship between the biomarkers and the Gleason
2 score/ISUP grade groups. Then the receiver operating characteristic (ROC) was also used to test the ability of
3 the biomarkers to predict aggressive prostate cancer (ISUP grade group 4 and 5). A biomarker with an area
4 under the ROC curve (AUROC) of 0.5 – 0.6 was considered to have failed, while 0.6 – 0.7 was a poor predictor
5 of aggressive prostate cancer. A biomarker with an AUROC of 0.7 – 0.8 was considered a fair predictor, 0.8 –
6 0.9 as a good predictor, and 0.9 – 1.0 was considered to be a very good predictor. All levels of statistical
7 significance were set as *p* <0.05. The health research and ethics committee of Usmanu Danfodiyo University
8 Teaching Hospital approved the study with reference number UDUTH/HREC/2019/No. 852.
9

1 **RESULTS.**

2

3　The study involved sixty-three participants, whose ages ranged from 43 to 102 years, with a mean age of 68.6

4　years ± 8.9 and a median age of 70 years (IQR 13). Of the participants, twenty-two (34.9%) were under 65

5　years old, 41 (65.1%) were over 65, and just one (1.6%) was under 50. The histogram in Figure 1 shows the

6　age distribution of the participants. Every participant had symptoms; 62 (98.4%) reported lower urinary tract

7　symptoms (LUTS), and 15 (24.2%) of them had an indwelling urethral catheter as a result of obstructive

8　nephropathy or urine retention. In Table 1, additional typical presenting symptoms are displayed. The mean

9　duration of symptoms before presentation was 20.4 months ±18.4. Twenty-nine (46%) participants had

10　comorbidity as listed in Table 2. Out of the 63 participants, 5 (7.9%) exhibited benign digital rectal examination

11　(DRE) findings and 58 (92.1%) had DRE findings suggesting prostate cancer.

12　In 20 (31.7%) of the participants, the urine culture yielded microorganisms as displayed in Table 3. Seven

13　(11.1%) subjects had elevated creatinine ±urea, whereas 53 (84.1%) had normal renal function test results. The

14　mean packed cell volume (PCV) was 31.7% ±4.7. The mean serum PSA was 65.9ng/ml ±38.6, ranging from

15　1.2ng/ml to 100ng/ml. Fifty-six (88.9%) participants had serum PSA above 10ng/ml while 4 (6.3%) participants

16　had serum PSA levels in the gray zone between 4 and 10ng/ml. Interestingly, 3 (4.8%) participants had normal

17　serum PSA <4ng/ml. Serum IMPDH-2 levels ranged from 0.25 pg/ml to 176.4 pg/ml, with a mean of 76.2 pg/ml

18　±55.1. The boxplot in Figure 2 displays the serum biomarkers' distribution.

19　The prostate ranged from 14.8 to 196 ml in size, with a mean of 67.9 ml ±36.2. Of the participants, 42 (66.7%)

20　had a breach of the prostate capsule, and 49 (78.8%) had prostatic nodules. Of those with prostatic nodules,

21　22 (44.9%) had hypoechoic nodules, 6 (12.2%) had isoechoic nodules, and 21 (42.9%) had mixed echoic

22　nodules. Twenty-seven (42.9 percent) of the participants had tumor invasion of the seminal vesicles. Of the 63

23　participants, forty-seven (74.6%) had a Gleason score of ≥8. Table 4 displays the distribution of the ISUP grade

24　group and Gleason score.

25　No significant correlation was seen between serum IMPDH-2 and ISUP grade group (τ = 0.03, p = 0.79, Kendall

26　tau) or between serum IMPDH-2 and Gleason score (r = 0.08, Spearman's rho, p = 0.55). Similarly, using linear

27　regression analysis, serum IMPDH-2 had no relationship with the Gleason score (B=0.001, P=0.56) and ISUP

28　grade group (B = 0.001, p = 0.78). The scatter plot in Figure 3 shows the lack of a linear relationship between

29　serum IMPDH-2 and the Gleason score. Furthermore, serum IMPDH-2 was only responsible for 0.6% (R^2 =

30　0.006) of the Gleason score variance and 0.1% (R^2=0.001) of the ISUP grade group variance. Nonetheless,

31　there was a positive correlation (r = 0.30, Spearman's rho, p = 0.02) between the serum PSA level and the

32　Gleason score. However, the correlation was weak. Serum PSA also had a very weak correlation (τ = 0.21, p =

33　0.04, Kendall tau) with the ISUP grade group. Using linear regression analysis, PSA had a positive relationship

34　with the Gleason score (B= 0.009, p = 0.01) and the ISUP grade group (B = 0.009, p = 0.02). It determined

35　10.1% (R^2 = 0.101) and 8.8% (R^2 = 0.088) of the Gleason score and ISUP grade group variances respectively.

36　The weak linear relationship of the PSA and Gleason score is displayed in Figure 4. Using the ROC curve, the

37　overall ability of serum PSA in predicting aggressive PCa (ISUP grade group 4 and 5) was fair with an area

38　under the curve of 0.74 (95% CI; 0.61 – 0.88) as shown in Figure 5. However, serum IMPDH-2 failed to predict

39　aggressive prostate cancer with an area under the curve of 0.52 (95% CI; 0.34 – 0.69) as shown in Figure 6.

40　However, when compared, the serum PSA did not considerably outperform IMPDH-2 (p = 0.53) in predicting

IJMS

1 the Gleason score. Consequently, neither serum PSA nor IMPDH-2 can be used in isolation to predict

2 aggressive prostate cancer.

3

IJMS

1 **DISCUSSION.**

2

3 It is worrisome that our patients still present late with locally advanced and occasionally metastatic prostate

4 cancer, even with the availability of PSA testing facilities. Furthermore, we frequently see patients with advanced

5 illnesses that progress to skeletal metastasis. To make informed management decisions and lower the morbidity

6 and death rate related to the condition, it is essential to identify individuals with high-grade, aggressive PCa

7 who are at risk of disease progression.

8 Age is a significant risk factor for prostate cancer and the majority of cases are diagnosed at 65 years or older

9 with the risk rising after the age of 50.[19] This study obtained comparable results, with a mean age of 68.6 years

10 and most participants being older than 65. The findings by Wieczorek et al.[14] in Poland and Odubanjo et al.[20] in

11 Nigeria were similar to ours reporting a mean age of 68.2 years and 68.5 years respectively. Similarly, Elabbady

12 et al.[21] in Egypt reported a mean age of 67 which is also not significantly different from ours. In Ghana, however,

13 Egote et al.[22] reported a higher mean age of 71.7 years. This may be either because their patients present late

14 or they may have less aggressive disease and hence late onset of symptoms.

15 Almost all our study participants had lower urinary tract symptoms (LUTS), indicating at least a locally advanced

16 illness. This indicated inadequate PCa screening practices, which can be linked to several factors including low

17 awareness, poverty, anxiety and fear of developing cancer, lack of urologists in primary and secondary

18 healthcare facilities, and a dearth of PSA testing facilities in rural areas. Yahaya et al.[23] also reported LUTS as

19 the most common form of presentation of their PCa patients. In contrast, Adewumi et al.[24] reported LUTS as

20 the second most common complaint after bone pain. In another study, Oyibo et al.[4] reported LUTS in three-

21 quarters of their study participants. However, Elabbady et al.[21] in Egypt, reported that a quarter of their PCa

22 patients were asymptomatic at diagnosis due to improved practice of PSA screening. In Lagos, Odubanjo et

23 al.[20] also reported 20% of their patients being asymptomatic at diagnosis possibly due to better PCa screening

24 awareness. According to their report, LUTS was still the most often reported form of presentation in 68.6% of

25 their patients. Based on the aforementioned studies, LUTS is a major form of presentation of PCa patients. This

26 may be attributed to locally advanced disease or coexisting benign prostatic hyperplasia.

27 Medical comorbidity affected over half of our participants; the majority had hypertension, and a small number

28 had diabetes mellitus. The presence of a medical co-morbidity in prostate cancer patients may constitute a

29 competing cause of mortality. This was buttressed by Stikbakke et al.[25] who reported that a systolic blood

30 pressure of >150 mmHg among PCa patients is associated with a 49% increase in overall mortality. Also, a

31 threefold increase in overall mortality risk was observed among prostate cancer patients with diastolic blood

32 pressure > 90mmHg treated with curative intent.[25] The small number of diabetics among our study participants

33 is in keeping with the findings by Kasper et al.[26] that diabetes has an inverse relationship with PCa. Ofoha et

34 al.[19] also reported that about half of their PCa patients had comorbidity with hypertension being the commonest.

35 The majority of participants' DRE was suspicious of PCa, supporting how late our patients presented. Oyibo et

36 al.[4] also reported similar findings as 90% of the patients in their study had suspicious DRE. In contrast, Elabbady

37 et al.[21] and Wieczorek et al.[14] reported less than a quarter of their study subjects with suspicious DRE which

38 reflects an earlier diagnosis of prostate cancer in their regions. The majority of individuals with positive urine

39 cultures were asymptomatic and had indwelling urethral catheters. According to studies, the duration of the

40 indwelling catheter is the main determining factor of catheter-associated bacteriuria. Catheter-associated

41 bacteriuria affects patients with an indwelling urethral catheter at a daily rate of 3 – 8%.[27]

1 The mean serum PSA level of our participants was 65.9ng/ml which is lower than 207.9ng/ml reported by Okolo

2 et al.[28], 82.9ng/ml reported by Oyibo et al.[4], and 73.4ng/ml reported by Ofoha et al.[19] but higher than 37.1ng/ml

3 reported by Egote et al.[22] These variations can be a result of the biology of the cancer cells or variations in the

4 ELISA kits used in the various studies. Even though the majority of participants had PSA levels above 10ng/ml,

5 a few had PSA levels below 4ng/ml. This suggests that certain patients with prostate cancer may not be detected

6 by the PSA threshold of 4ng/ml, which is why additional clinical and radiological parameters are necessary. This

7 was also corroborated by Odubanjo et al.[20] who reported that 3% of their PCa patients had PSA <4ng/ml. The

8 mean serum level of IMPDH-2 in our study was higher than the 60.5 that Wieczorek et al.[14] The difference

9 observed in both studies may be due to different ELISA kits, tumor biology, population characteristics, or sample

10 size. This is because our sample size is larger than theirs and our study population is black compared to the

11 white study population in Poland.

12 The mean size of the prostate was 67.9ml which is similar to 67.2ml reported by Oyibo et al.[4] also in Nigeria,

13 but slightly higher than the 63ml reported by Elabbady et al.[21] The majority of research participants had a

14 breached prostatic capsule, and nearly half of them had tumor invasion of one or both seminal vesicles,

15 indicating at least a locally advanced disease. Oyibo et al.[4] likewise stated that 85% of their patients had a

16 capsular breach. Prostatic nodules on TRUS were present in most of our research participants. These nodules

17 were primarily hypoechoic or mixed echoic. The study by Manseck et al.[29] also reported hypoechoic lesions in

18 34.5% of all biopsy cores making it the most common lesion associated with PCa. The majority of the research

19 participants had Gleason scores of 8 or above (ISUP grade group 4 and 5) which emphasizes the

20 aggressiveness of prostate cancer in these individuals. Prior research has revealed that black and Asian

21 individuals had germline mutations linked to high-risk prostate cancer.[30] Oyibo et al.[4] reported that 52% of their

22 study participants had Gleason scores of 8-10 which is lower than ours. Ngwu et al.[31] reported less than a

23 quarter of their patients, 18.2% with a Gleason score of 8 – 10. Only 4.8% of our study participants had a

24 Gleason score of 6 which is lower than the 32.5% that was reported by Oyibo et al.[4] In contrast to our study

25 Elabbady et al.[21] and Wieczorek et al.[14] reported Gleason scores of ≤7 as the most common Gleason scores in

26 their respective studies. This shows that Arabs and Caucasians are more likely to have less aggressive prostate

27 cancer compared to blacks.

28 Our research revealed that the Gleason score and ISUP Grade groups could not be predicted by serum IMPDH-

29 2. This is in contrast to the finding of Wieczorek et al.[14] who reported a weak positive correlation between serum

30 IMPDH-2 and ISUP grade group (τ = 0.4, p = 0.005, Kendall tau). Variances in the ELISA kits used in the two

31 research, differences in sample size, or even variations in tumor biology related to race or ethnicity could be

32 responsible for the disparities observed between the two studies. Serum PSA did, however, showed a very

33 weak positive correlation with ISUP Grade groups and a weak positive correlation with the Gleason score. This

34 further affirms PSA as a weak predictor of aggressive prostate cancer. Additionally, 10.1% of the variance in

35 the Gleason score was dictated by serum PSA. Thus, about 80% of the Gleason score variance can be

36 attributed to other causes. Okolo et al.[28] and Oyibo et al.[4] both in Nigeria, also reported a weak positive

37 correlation of 0.4 between serum PSA and Gleason score. Likewise, Ngwu et al.[31] reported a positive

38 association between serum PSA and Gleason score (r = 0.6) with a moderate strength. Ngowi et al.[3] in Tanzania

39 also reported weak ability of serum PSA in predicting aggressive PCa with an AUC of 0.71 which is not different

40 from ours. However, in a study by Mohammed et al.[32] there was no correlation between PSA and Gleason score

41 (p = 0.175). Most of the aforementioned studies showed that serum PSA could predict aggressive PCa.

12

1 However, it is not an accurate biomarker, and therefore, at most, it should be used in combination with other

2 markers and parameters such as Gleason score, number, and percentage of prostate biopsy core involvement

3 among others to predict aggressive prostate cancer. Serum IMPDH-2 did not predict aggressive prostate

4 cancer. There is a need to intensify further research into other biomarkers and advanced imaging techniques

5 including functional imaging that may predict aggressive prostate cancer with high accuracy.

6

7 **Conclusion**

8 Serum PSA is a weak predictor of aggressive prostate cancer. It was responsible for 10.1 and 8.8% of the

9 Gleason score and ISUP grade group variances. However, serum IMPDH-2 could not predict aggressive

10 prostate cancer. Even though serum PSA weakly predicted aggressive prostate cancer, it was not statistically

11 better than serum IMPDH-2. Therefore, neither of the two biomarkers can reliably predict aggressive prostate

12 cancer, especially when used in isolation. Hence, further studies need to be done to search for better predictors

13 of aggressive prostate cancer.

14

15

1 **SUMMARY - ACCELERATING TRANSLATION**

2

3 **Comparison of Serum PSA and IMPDH-2 as Predictors of Aggressive Prostate Cancer: A Cross-**
4 **sectional Study**

5

6 **Main Problem to Solve:** Prostate cancer is a major cause of morbidity and mortality globally. It is the most
7 common male cancer among Nigerian men. Most of our patients present with locally advanced and metastatic
8 disease. Serum PSA is not accurate in discriminating aggressive from indolent prostate cancer. Even though
9 the Gleason score and ISUP grade group are more accurate than PSA in that regard, they require a biopsy.
10 Prostate biopsy is an invasive procedure and foci of high-grade disease can be missed. Therefore, some
11 patients with aggressive prostate cancer can be missed using the Gleason score and ISUP grade. Therefore,
12 a reliable, accessible, and affordable screening modality is required to improve the diagnosis of aggressive
13 prostate cancer.

14

15 **Aim of the Study:** This article aims to compare serum prostate-specific antigen and Inosine Monophosphate
16 Dehydrogenase 2 in predicting aggressive prostate cancer.

17

18 **Methodology:** Sixty-three prostate adenocarcinoma patients were recruited for this quantitative descriptive
19 cross-sectional study. Their serum was assayed for IMPDH-2 and PSA. Serum IMPDH-2 and PSA correlations
20 with Gleason score and ISUP Grade Groups were determined using Spearman's rho and Kendall tau correlation
21 coefficients, respectively. The magnitude of the correlation was assessed by calculating the coefficient of
22 determination for the respective analysis (R^2). Similarly, regression analysis and receiver operating
23 characteristic (ROC) curve were used to assess the ability of the biomarkers to predict aggressive prostate
24 cancer. Levels of statistical significance were set as $p < 0.05$.

25

26 **Results:** The mean age was 68.6 years. All the recruited participants were symptomatic. The mean serum
27 IMPDH-2 and PSA were 76.2pg/ml and 65.9ng/ml respectively. Serum IMPDH-2 did not correlate with the
28 Gleason score ($r = 0.08$, $p = 0.55$ Spearman rho) and ISUP grade group ($\tau = 0.03$, $p = 0.79$ Kendal tau). Similarly,
29 using linear regression analysis, serum IMPDH-2 had no relationship with the Gleason score (B=0.001, P=0.56)
30 and ISUP grade group (B = 0.001, $p = 0.78$). It also failed to predict aggressive prostate cancer (ISUP grade
31 group 4 and 5) using the ROC curve with an area under the curve of 0.52 (95% CI; 0.34 − 0.69). Therefore,
32 IMPDH-2 is not a good predictor of aggressive prostate cancer. However, serum PSA weakly correlated with
33 Gleason score ($r = 0.30$, $p = 0.02$ Spearman rho) and ISUP grade group ($\tau = 0.21$, $p = 0.04$ Kendal tau). It was
34 responsible for 10.1 and 8.8% of Gleason score and ISUP grade group variances respectively. Similarly, using
35 regression analysis, there was a weak linear relationship between PSA and both the Gleason score (B= 0.009,
36 $p = 0.01$) and the ISUP grade group (B = 0.009, $p = 0.02$). The overall ability of serum PSA in predicting
37 aggressive PCa (ISUP grade group 4 and 5) was fair with an area under the curve of 0.74 (95% CI; 0.61 − 0.88).
38 However, when compared, serum PSA did not significantly outperform IMPDH-2 in predicting the Gleason score
39 ($p = 0.53$).

40

1 **Conclusion:** Serum PSA weakly predicted aggressive prostate cancer but did not statistically significantly

2 outperform IMPDH-2. It was responsible for 10.1 and 8.8% of Gleason score and ISUP grade group variances.

3 Therefore, neither PSA nor IMPDH-2 is sufficiently accurate in predicting aggressive prostate cancer when used

4 in isolation.

5

REFERENCES.

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
2. Popoola AO. Prevalence and pattern of cancers among adults attending a tertiary health institution in Lagos, Nigeria. IOSR J Dent Med Sci. 2013;6(3):68-73.
3. Ngowi BN, Mremi A, Seif MJ, Kyara YS, Mteta VK, Bright F, et al. Prostate cancer: burden and correlation with prostate specific antigen among screened African men in Tanzania. Res Rep Urol. 2024;16:315-325.
4. Oyibo EU, Umar MA, Abdullahi K, Muhammad SA, Agwu PN. Clinicopathological correlates of patients with prostate cancer in a tertiary hospital in northwestern Nigeria. Orient Journal of Medicine. 2023;35(1-2):1-10.
5. Ojewola RW, Tijani KH, Jeje EA, Ogunjimi MA, Anunobi CC, Adesanya AO. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population: experience in a Nigerian teaching hospital. West Afr J Med. 2013;32(1):8-13.
6. Oluwole OP, Rafindadi AH, Shehu MS, Samaila MOA. A ten-year study of prostate cancer specimens at Ahmadu Bello University Teaching Hospital Zaria, Nigeria. Afr J Urol. 2015;21(1):15-18.
7. Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. 1999;91(3):159-164.
8. Wang C, Höti N, Lih TSM, Sokoll LJ, Zhang R, Zhang Z, et al. Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA. Clin Proteomics. 2019;16:13.
9. Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016;11:25.
10. Chen N, Zhou Q. The evolving Gleason grading system. Chin J Cancer Res. 2016;28(1):58.
11. He Y, Zheng Z, Xu Y, Weng H, Gao Y, Qin K, et al. Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma. Am J Cancer Res. 2018;8(8):1604.
12. Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109(7):2903-2928.
13. Xu Y, Zheng Z, Gao Y, Duan S, Chen C, Rong J, et al. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma. Sci Rep. 2017;7:745. doi:10.1038/s41598-017-00887-1
14. Wieczorek P, Bałut-Wieczorek M, Jasinski M, Szabłoński W, Antczak A. Inosine monophosphate dehydrogenase 2 as a marker of aggressive and advanced prostate cancer. Cent European J Urol. 2018;71(4):399-403.
15. Awosan KJ. Student friendly statistics for health, life, and social sciences. Lagos: Somerest Ventures; 2020
16. Monobind. PSA AccuBind Elisa kit (product code 2125-300). Available from: https://www.monobind.com/immunoassays-cancer-markers-psa. Cited January 7, 2021.
17. Sunlong Biotech. Human inosine monophosphate dehydrogenase 2 (IMPDH2) ELISA kit Instruction manual. Available from: https://www.sunlongbiotech.com. Cited January 7, 2021
18. Moore DS, Notz WI, Flinger MA. The basic practice of statistics. 6th ed. New York. W H Freeman; 2013.
19. Ofoha CG, Magnus FE. Presentation, characteristics and co-morbidities of men with prostate cancer in Nigeria. J Adv Med Res. 2019;31(5):1-7.
20. Odubanjo MO, Banjo AA, Ayoola S, Abdulkareem FB, Anunobi CC, Olayinka AA. The clinicopathologic pattern of prostatic carcinoma in Lagos, Nigeria. N A J Med Sci. 2013;6(2). 71-75.
21. Elabbady A, Eid A, Fahmy A, Kotb AF. Pattern of prostate cancer presentation among the Egyptian population: A study in a single tertiary care center. Cent European J Urol. 2014;67(4):351-356.
22. Egote AK, Ossei PPS, Agyeman-Duah E, Taylor J, Quarshie E. Patterns and presentation of prostate cancer in the Brong Ahafo region of Ghana: a 6-year single center retrospective study. Health. 2019;11(4):351-360.
23. Yahaya JJ. Clinical and histopathological profile of patients with prostate cancer in Kampala, Uganda. Med J Zamb. 2019;46(1):19-27.
24. Adewumi AO, Anthonia SC, Alabi AS, Amina FO, Kingsley KK. Pattern of prostate cancer among a Nigerian population: a study in a single tertiary care centre. Niger J Med. 2016;25(1):70-76.
25. Stikbakke E, Schirmer H, Knutsen T, Støyten, M, Wilsgaard T, Giovannucci EL, et al. Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study. Cancer Med. 2022;11(4):1005-1015.

16

26. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056-2062

27. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults. Clin Infect Dis. 2010;50(5):625-663.

28. Okolo CA, Akinosun OM, Shittu OB, et al. Correlation of serum PSA and Gleason score in Nigerian men with prostate cancer. Afr J Urol. 2008;14(1):15-22.

29. Manseck A, Guhr K, Hakenberg O, Rossa K, Wirth MP. Clinical significance of the echogenicity in prostatic ultrasound findings in the detection of prostatic carcinoma. Onkologie. 2000; 23(2):151-156.

30. Okoye JO. High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review. Avicenna J Med. 2020;10(3):93-101.

31. Ngwu PE, Achor GO, Eziefule VU, Orji JI, Alozie FT. Correlation between Prostate Specific Antigen and Prostate Biopsy Gleason Score. Annals of Health Research. 2019;5(2):243-248.

32. Mohammed U, Rasheed MW, Adegboye AT, Abdullahi K, Sahabi SM, Mohammed TO, et al. Correlation of serum PSA with Gleason score and Gleason group grade in patients with prostate adenocarcinoma at Sokoto north-western Nigeria. Intl J Recent Innov Med Clin Res. 2024;2(2):6-13.

1 **FIGURES AND TABLES.**

2

3

4 **Figure 1.** A histogram showing the age distribution of the study subjects

5

6

7

8

1 **Figure 2.** Boxplot Showing the Maximum, Minimum, Median, and Interquartile Range of Serum PSA and
2 IMPDH-2
3

4
5

IJMS

1   **Figure 3.** A Scatter Plot Showing the Absence of a Linear Relationship Between IMPDH-2 and Gleason Score

2

3
4

20

1 **Figure 4.** A Scatterplot Showing the Weak Linear Relationship Between PSA and Gleason Score
2

3
4

21

1 **Figure 5.** The ROC Curve for Serum PSA Showing some Usefulness of PSA in Diagnosing Aggressive
2 Prostate Cancer.
3

ROC FOR PSA.

4
5

1 **Figure 6.** The ROC Curve for Serum IMPDH-2 Showing its Poor Usefulness in Diagnosing Aggressive
2 Prostate Cancer
3

ROC CURVE FOR IMPDH-2.

4

1   **Table 1**. The Presenting Symptoms of the Study Population with Prostate Cancer

2

PRESENTING SYMPTOMS	FREQUENCY	PERCENTAGE
Voiding LUTS[a]	62	98.4
Storage LUTS[a]	61	96.8
Low Back Pain	36	57.1
Lower limb Paraesthesia	28	44.4
Paraparesis/Paraplegia	14	22.2
Weight Loss	16	25.4
Body Weakness	14	22.2
Anorexia	14	22.2
Urinary Incontinence	3	4.8
Faecal Incontinence	2	3.2
Pressure Ulcer	2	3.2
Hematuria	1	1.6

3   [a] Lower Urinary Tract Symptoms

4

5

6

1 **Table 2**. List of Comorbidities Among the Study Population with Prostate Cancer

2

3

CO-MORBIDITY	FREQUENCY	PERCENTAGE
Nil	34	53.9
hypertension	21	33.3
Diabetes Mellitus	3	4.8
Hypertension & Diabetes Mellitus	2	3.2
Hypertension & CKD[a]	1	1.6
Cerebrovascular Disease	1	1.6
Cardiac Failure	1	1.6
TOTAL	**63**	**100**

4 [a] Chronic Kidney Disease

5
6

Table 2. List of Comorbidities Among the Study Population with Prostate Cancer

1   **Table 3**. List of Microorganisms Cultured in the Urine of the Study Population with Prostate Cancer

2

MICROORGANISM	FREQUENCY	PERCENTAGE
Escherichia coli	7	11.1
Staphylococcus aureus	5	7.9
Klebsiella	3	4.8
Proteus mirabilis	2	3.2
Candida albicans	2	3.2
Pseudomona specie	1	1.6
Negative Culture	43	68.2
Total	**63**	**100**

3

1   **Table 4**. The Gleason Score and ISUP Grade Groups of the Study Population with Prostate Cancer

2

VARIABLE		FREQUENCY	PERCENTAGE
GLEASON SCORE	6	3	4.8
	7	13	20.6
	8	17	27
	9	22	34.9
	10	8	12.7
TOTAL		**63**	**100**
ISUP[a] GRADE GROUP	1 (GS[b] ≤6)	3	4.8
	2 (GS 3 + 4)	6	9.5
	3 (GS 4 + 3)	7	11.1
	4 (GS 8)	17	27
	5 (GS 9 & 10)	30	47.6
TOTAL		**63**	**100**

3   [a] International Society of Urologic Pathologists

4   [b] Gleason score

5

27

IJMS